Phaseline

Companies › Byondis

Byondis: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rituximab (BYON4228)
B-lymphocyte antigen CD20 binding agent
MS4A1, SIRPAPhase 1Lymphoma; Solid TumorDec 2026
BYON4413–Phase 1Relapsed / Refractory AML–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06359002BYON4413Phase 1Relapsed / Refractory AMLOncologySep 2025
NCT05737628Rituximab (BYON4228)Phase 1LymphomaOncologyFeb 2026
NCT06932952Rituximab (BYON4228)Phase 1Solid TumorOncologyDec 2026

Targets

MS4A1 (1) SIRPA (1)

Companies with the same targets

Roche Biocad Acerta Pharma FBD Biologics Regeneron Pharmaceuticals Sandoz Celltrion TG Therapeutics Genmab Novartis

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.